6月2日 - ** 药物开发商Kymera Therapeutics KYMR.O股价盘前上涨39.16%至41.25美元
** 该公司称 (link)，其实验性口服药物在早期试验中显示血液和皮肤中STAT6降解强劲
** 这种名为KT-621的药物靶向STAT6--一种在免疫反应中起关键作用的信号蛋白
** 公司称，即使单次剂量低至 6.25 毫克，STAT6 降解率也超过了 90% 的目标值
** KT-621对Th2免疫反应生物标志物的影响与赛诺菲SASY.PA和Regeneron的REGN.O Dupixent - KYMR一致或更优
** 研究发现，KT-621与安慰剂一样安全，没有出现严重不良事件
** 截至上一交易日收盘，Kymera股价年累计下跌约26
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.